Orforglipron
Also known as: LY3502970, OWL833
Primary recreational use: Weight loss and diabetes control
What is Orforglipron?
Orforglipron is an oral, non-peptide GLP-1 receptor agonist developed by Chugai Pharmaceuticals and licensed to Eli Lilly. It is primarily used for significant weight loss and glycemic control in diabetes. Currently, it is in Phase 3 clinical trials for diabetes and obesity, and FDA approval is expected in 2026. Although promising, it poses risks such as gastrointestinal discomfort and increased gallbladder disease risk with rapid weight loss.
Primary Benefits
Significant weight loss. Robust diabetes control. Reduced cardiovascular risk markers.
How It Works
Orforglipron binds to GLP-1 receptors and activates the G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite. Being a non-peptide allows it to have high oral bioavailability without the need for complex formulations.
Safety Tips
Precautions reported in community discussions and literature. This is not a complete list.
- 1.DON'T start with a high dose - begin with the lowest effective dose to assess tolerance.
- 2.NEVER double dose to make up for a missed tablet.
- 3.DON'T store the tablets outside recommended temperatures (15-30°C).
- 4.AVOID using if pregnant or breastfeeding.
- 5.DON'T use Orforglipron without medical supervision due to investigational status.
Use Contexts
Different purposes have different protocols, dosing, and considerations
Weight loss in obesity
strong evidenceUsed to induce significant weight loss in obesity without diabetes, showing up to 12.4% weight loss in clinical trials.
Evidence: Phase 3 clinical trials show strong evidence of efficacy in overweight individuals without diabetes.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Any time of day
Notes: Consistency in daily timing helps compliance.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Weight loss initiation | 6mg | once daily | Oral tablet |
| Weight loss optimization | 36mg | once daily | Oral tablet |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Potential increased risk of gallbladder disease
Storage
Diabetes management
strong evidenceUsed for managing Type 2 Diabetes with robust glycemic control and HbA1c reductions in clinical trials.
Evidence: Phase 3 trials demonstrate effectiveness in reducing HbA1c by 1.3-1.6%.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Any time of day
Notes: Can be taken consistently at the same time for optimal effects.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Type 2 diabetes initiation | 3mg | once daily | Oral tablet |
| Type 2 diabetes optimal control | 36mg | once daily | Oral tablet |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Monitor for signs of acute pancreatitis
Storage
Harm Reduction Information
Quality Concerns
- Potential for counterfeit and substandard products from unregulated sources.
Safety Tips
- Start with a lower dose to assess individual response.
- Ensure proper daily adherence to dosing schedule.
- Store tablets as per guidelines to maintain efficacy.
Warning Signs to Stop
- Severe abdominal pain suggesting pancreatitis
- Allergic reactions such as hives or difficulty breathing
Seek Medical Help Immediately If
- Signs of pancreatitis or serious allergic reactions occur
Frequently Asked Questions
Common questions about Orforglipron
How long until I see effects?
Orforglipron effects such as appetite reduction can be seen within 1-3 days, with glucose improvements in 1-4 weeks.
What time of day should I take it?
Orforglipron can be taken at any time of the day, with or without food, for optimal compliance.
How can I minimize side effects?
Start Orforglipron at the lowest effective dose and escalate gradually every 4 weeks to minimize GI side effects.
Does tolerance develop?
Orforglipron does not typically lead to tolerance, but long-term studies are ongoing.
How should I store it?
Orforglipron should be stored at room temperature (15-30°C), protected from moisture and heat.
Do I need to cycle it?
Orforglipron is typically used in long-term continuous therapy without specific cycling.
Can I combine it with other peptides?
Orforglipron can be combined with certain peptides like Dapagliflozin, but avoid combining with Semaglutide or Liraglutide.
What happens if I miss a dose?
If you miss an Orforglipron dose, take it as soon as you remember on the same day. If it's the next day, skip the missed dose.
Reported Combinations
Compounds reported to be used alongside Orforglipron in community discussions
Dapagliflozin
Both improve glycemic control and complement metabolic effects.
Metformin
Enhanced glycemic control in diabetes management.
Healthy diet
Supports weight loss and metabolic health.
Reported Interactions
Interactions reported in literature and community discussions.
Avoid due to potential adverse interactions.
May require dose adjustment to prevent hypoglycemia.
Generally well-tolerated when combined.
Dose adjustments may be necessary to avoid hypoglycemia.
Reconstitution Calculator
100 units = 1 mL
Safety Tips
- Always consult a licensed medical professional for dosing and reconstitution instructions.
- Always double check your units. Mixing up mg and mcg can be very dangerous.
- Make sure to select your syringe type. U-100 and U-50 syringes have different units.
- Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.
This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.
Legal Status by Region
Regulatory status varies by country
USA
investigational
UK
investigational
EU
investigational
Australia
investigational
Canada
investigational
Explore More Research
Browse our database of peptide research information compiled from published literature and community sources.
Citations
Last updated: October 5, 2023